Biomethodes

Hospices Civils De Lyon

Stephane Blesa

Marc Delcourt

Bruno Winter

Jean-Luc Plantier

Helene Chautard

Laurent Mesta

Didier Saboulard

Thierry Menguy

Sylvie Marin

Claude Negrier

The present invention provides the field of enhancing proteins and in particular to that of proteins enhanced by molecular change. It provides a variant of a phytase that is termed enhanced in that is has better thermostability and/or activity than the original phytase. The invention also provides a nucleic acid coding for said variant, a cassette or an expression vector containing said variant, a host cell expressing said variant, a composition comprising said variant and uses thereof, principally in the preparation of food additives and animal feed.

Enhanced phytase variants

The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.

VIII factors for the treatment of type A hemophilia

The invention concerns the field of molecular biology and more particularly that of mutagenesis. It concerns a method of high-rate directed mutagenesis, that is the formation of numerous directed mutants in reduced time and with reduced number of steps. Said method is therefore referred to as massive mutagenesis.

Method for massive directed mutagenesis

Growing community of inventors

Grisy-Suisnes, France

Stephane Blesa